维普中文期刊产品整合服务
27篇 您的检索式:作者名="Fleck RA"
    题名 作者 年代 出处 被引量
1Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, doubleblind, placebo-controlled study 显示文摘DeFronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,12:1
2Maturational alterations in gap junction expression and associated collagen synthesis in response to tendon function显示文摘Young NJ Becker DL Fleck RA 0,,06:1
3Use of HL-60 cell line to measure opsonic capacity of pneumococcal anti- bodies 显示文摘Fleck RA Romero-Steiner S Nahm MH 2005Clin Diagn Lab Immuno12005,12,1:1
4Efficacy and tolerability of the DPP-4 inhibitor + + alogliptin combined with pioglitazone, in mefformin-treated patients with type 2 diabetes 显示文摘DeFronzo RA Burant CF Fleck P 2012J Clin Endocfinol Metab2012,97,5:1
5Closure behaviour of surface cracks显示文摘Fleck NA Smith IFC Smith RA 1983Fatigue Fract Eng Mater Struct1983,6,3:1
6Transcutaneous oxygen levels in retinopathy of prematurity 显示文摘Cunningham S Fleck BW Ehon RA 1995Lancet1995,346,8988:1
7Efficacy and safety ofthe dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type2 diabetes and inadequate glycemic control:a randomized double-blind,placebo-controlled study显示文摘DeFronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,12:1
8Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with piogli- tazone, in metformin-treated patients with type 2 diabetes显示文摘DEFRONZO RA BURANT CF FLECK P 2012J Clin Endocrinol Metab2012,97,5:1
9Use of HL-60 cell lineto measure opsonic capacity of pneumococcal antibodies显示文摘Fleck RA Romero-Steiner S Nahm MH 2005ClinDiagn Lab Immunol2005,12,1:1
10Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control : a randomized, double- blind, placebo-controlled study 显示文摘DeFronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,12:1
11Efficacy and safety of the dipeptidy 1 peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double blind, placebo-controlled study显示文摘Defronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,12:1
12Anti-prothrombin antibodies and the lupus anticoagulant显示文摘Fleck RA Rapaport SI Rao LV 0,,02:1
13Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study显示文摘Defronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,12:1
14Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control:a randomized,double-blind,placebo-controlled study显示文摘DeFronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,:1
15Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies 显示文摘Fleck RA Romero-Steiner S Nahm MH 2005Clin Diagn Lab Immunol2005,12,1:1
16Elucidation of the metabolic and structural basis for the cryopreservation recalcitrance of Vaucheria sessilis显示文摘Fleck RA Day JG Clarke KJ 0,,:1
17Efficacy and safety of the dipeptidyl peptidase-d inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study显示文摘DEFRONZO RA FLECK PR WILSON CA 2008Diabetes Care2008,31,12:1
18Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control显示文摘Defronzo RA Fleck PR Wilson CA 2008Diabetes Care2008,31,12:1
19Efficacy and safety of the dipeptidyl peptldase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study显示文摘DEFRONZO RA FLECK PR WILSON CA 2009Curr Med Res Opin2009,25,10:1
20Confocal microscopy study of pertussis toxin and toxoids on CHO-cells显示文摘Tan Y Fleck RA Asokanathan C 2013Hum Vaccine Immunother2013,9,2:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费